Ulysses Management’s Pfizer PFE Stock Holding History

Ulysses Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-40,000	Closed	-$1.47M	–	56
2023 Q2	$1.47M	Hold	40,000	–	–	0.13%	36
2023 Q1	$1.63M	Buy	+40,000	New	+$1.73M	0.34%	31

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ulysses Management's PFE Position: Q3 2023 in Review

Ulysses Management sold out of Pfizer (PFE) in Q3 2023, closing a stake of 40,000 shares — an estimated $1.47M sold.

Ulysses Management first reported a position in PFE in Q1 2023 and held it in 2 quarters. The position peaked at $1.63M in Q1 2023. 2,925 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

Ulysses Management reported no remaining Pfizer position as of Q3 2023 after selling out during the quarter.
Ulysses Management sold 40,000 Pfizer shares in Q3 2023, an estimated $1.47M.
Ulysses Management first reported a position in Pfizer in Q1 2023 and held it in 2 quarters.
Ulysses Management's Pfizer position peaked at $1.63M in Q1 2023.
2,925 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on Ulysses Management's 13F filing for Q3 2023, filed 14 Nov 2023.